Tiziana Life Sciences (AIM: TILS) has acquired the exclusive worldwide rights for NI-1201, a fully human anti-interleukin-6 receptor (IL-6R) monoclonal antibody (MAb), from privately-held Swiss biotech Novimmune.
The UK clinical-stage biotech company, which develops targeted drugs for cancer, autoimmune and inflammatory diseases, agreed to an upfront cash payment, milestone payments, and a royalty on future sales. The figures involved were not disclosed.
Monoclonal antibodies against IL-6R have been explored as potential drugs to treat inflammation in the past. NI-1201’s unique mechanism, however, is thought to have the potential to considerably increase anti-inflammatory activity.
This article is accessible to registered users, to continue reading please register for free. A free trial will give you access to exclusive features, interviews, round-ups and commentary from the sharpest minds in the pharmaceutical and biotechnology space for a week. If you are already a registered user please login. If your trial has come to an end, you can subscribe here.
Login to your accountTry before you buy
7 day trial access
Become a subscriber
Or £77 per month
The Pharma Letter is an extremely useful and valuable Life Sciences service that brings together a daily update on performance people and products. It’s part of the key information for keeping me informed
Chairman, Sanofi Aventis UK
Copyright © The Pharma Letter 2024 | Headless Content Management with Blaze